Please assess the completion status of the following clinical trial:

Trial Title: Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In good health~* Negative clinical history of varicella, zoster, measles, mumps, rubella, diptheria, tetanus, pertussis, invasive Hib disease and hepatitis B~* Had completed either a 2-dose primary series of PedvaxHIB or COMVAX or any 3-dose primary series of a licensed Hib vaccine~* Had received 2 or 3 doses of any hepatitis B vaccine or COMVAX prior to entry into trial~Exclusion Criteria:~* Previous receipt of measles, mumps, rubella or varicella vaccine either alone or in combination~* Any immune impairment or deficiency~* Recent household, daycare or school exposure to invasive Hib disease or hepatitis B~* Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination~* Vaccination with an inactive vaccine with in the past 14 days~* Vaccination with a live vaccine within the past 30 days~* Receipt of immune globulin, blood transfusion or blood-derived product in the past 3 months~* Recent history of fever or underlying medical problems

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): ProQuad + Tripedia + Comvax at Day 0 (Concomitant)
- 2 (Type: EXPERIMENTAL): ProQuad at Day 0, Tripedia + Comvax at Day 42(Nonconcomitant)
- 3 (Type: ACTIVE_COMPARATOR): Varivax + M-M-R II at Day 0, Tripedia + Comvax at Day 42 (Control)

Based on this trial design, predict the completion outcome and termination type (if applicable).